Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Centre Hospitalier St Anne
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
69High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03075657CT.gov Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia | — | Completed | — | — | — |
NCT02600741CT.gov Family Intervention in Recent Onset Schizophrenia Treatment (FIRST) | — | Completed | — | — | — |
NCT02431702CT.gov A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform | — | Completed | — | — | — |
NCT02307396CT.gov Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients | — | Completed | — | — | — |
NCT02374567CT.gov Pharmacovigilance in Gerontopsychiatric Patients | — | Terminated | — | — | — |
NCT02199743CT.gov Lurasidone Effects on Tissue Glutamate in Schizophrenia | — | Completed | — | — | — |
NCT03019887CT.gov Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction | — | Completed | — | — | — |
NCT01136772CT.gov A Comparison of Long-acting Injectable Medications for Schizophrenia | — | Completed | — | — | — |
NCT01161277CT.gov Effects of Aripiprazole and Haloperidol on Mesolimbic System Functioning | — | Completed | — | — | — |
NCT01193166CT.gov Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital | — | Withdrawn | — | — | — |
Show 20 more trialsShow fewer
NCT01157351CT.gov 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated | — | Completed | — | — | — |
NCT01164059CT.gov Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia | — | Completed | — | — | — |
NCT00723606CT.gov A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation | — | Completed | — | — | — |
NCT00859872CT.gov Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia | — | Completed | — | — | — |
NCT01052389CT.gov Pragmatic RCT Comparing Aripiprazole, Olanzapine and Haloperidol in the Treatment of Schizophrenia | — | Completed | — | — | — |
NCT00493233CT.gov Antipsychotic Polypharmacy in Schizophrenia | — | Completed | — | — | — |
NCT00156065CT.gov Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785) | — | Completed | — | — | — |
NCT00156104CT.gov Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED) | — | Completed | — | — | — |
NCT00947375CT.gov Lamictal TM, Haloperidol Decanoate in Schizophrenia | — | Terminated | — | — | — |
NCT00485901CT.gov Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia | — | Completed | — | — | — |
NCT00191555CT.gov Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment | — | Completed | — | — | — |
NCT00044044CT.gov A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia | — | Completed | — | — | — |
NCT00159081CT.gov One Year Drug Treatment in First-Episode Schizophrenia | — | Completed | — | — | — |
NCT00157378CT.gov Optimization of Acute Treatment in First Episode Schizophrenia | — | Unknown | — | — | — |
NCT01123408CT.gov Clozapine and Olanzapine Treatment of Aggression | — | Completed | — | — | — |
NCT00018850CT.gov 5HT3 Antagonism and Auditory Gating in Schizophrenia | — | Completed | — | — | — |
NCT00007774CT.gov To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia | — | Completed | — | — | — |
NCT00253110CT.gov A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder | — | Completed | — | — | — |
NCT00169091CT.gov Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia | — | Terminated | — | — | — |
NCT00189995CT.gov Clozapine IM and Aggression in Schizophrenic Patients | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Schizophrenia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Eukystol (this asset) | Centre Hospitalier St Anne | Approved | BB · 67 |
| Trospium | European Group for Research In Schizophrenia | P4 | BBB |
| Xanomeline | European Group for Research In Schizophrenia | P4 | BBB |
| Lurasidone | Aziende Chimiche Riunite Angelini Francesco S.p.A | P4 | BBB |
| Asenapine | Noven Pharmaceuticals, Inc. | P4 | BBB |
| Brexpiprazole | Humanis Saglık Anonim Sirketi | P4 | BBB |
| Bitopertin | Hoffmann-La Roche | P3 | BBB |
| Raloxifene | Shanghai Mental Health Center | P4 | BBB |
| Iloperidone | Vanda Pharmaceuticals | P4 | BBB |
+42 more in the Schizophrenia cohort
Other indications for Eukystol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Psychotic Disorder | — | P4 | BBB · 76 |
| Schizoaffective Disorder | — | P4 | BBB · 72 |
| Headache Disorder | — | P4 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Eukystol in Schizophrenia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/eukystol-schizophrenia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →